Drugs / MGN1601
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01265368 | Nov 2010 → Aug 2013 | renal cell carcinoma | Mologen AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGN1601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01265368 ↗ |
| Modality | Vaccine | “a intradermally administered tumor vaccine (MGN1601)” NCT01265368 ↗ |
| Route | Other | “will be administered intradermally” NCT01265368 ↗ |